MEDIKIT (7749) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Cumulative results for Q3 of the fiscal year ending March 2026 posted higher revenue and profit, although the increase in SG&A expenses constrained earnings growth. Revenue was ¥18.47B (¥17.34B in the same period of the previous year, +6.5%), Operating Income was ¥3.66B (¥3.63B, +0.8%), Ordinary Income was ¥3.80B (¥3.70B, +2.6%), and Net Income was ¥2.24B (¥2.16B, +3.8%). The gross profit margin improved by approximately 0.1pt year on year to 39.1%; however, SG&A expenses increased by +13.8%, outpacing revenue growth, and the Operating Income margin declined by approximately 1.1pt from 20.9% in the previous year to 19.8%. While the benefits of higher revenue were largely secured, the deterioration in operating leverage due to front-loaded expenses was a key characteristic of the results.

Factors Affecting Performance

【Revenue】Revenue was ¥18.47B, up +6.5% year on year. As the Company operates a single segment covering the manufacture and sale of medical devices, segment-specific drivers of changes have not been disclosed; however, performance has progressed at a pace largely consistent with the full-year Company forecast of ¥24.00B (+6.4%). The progress rate for cumulative Q3 results was 76.9%, exceeding the standard progress rate of 75%.

【Earnings】Gross profit was ¥7.22B, and the gross profit margin improved slightly year on year to 39.1%. Meanwhile, SG&A expenses increased to ¥3.57B, up +13.8% year on year, expanding at a pace exceeding revenue growth; consequently, the Operating Income margin declined to 19.8% (20.9% in the previous year). Non-operating income and expenses resulted in net income of ¥0.14B, boosting Ordinary Income to ¥3.80B (+2.6%). Extraordinary income and expenses consisted solely of a ¥0.03B gain on the sale of fixed assets, limiting the impact on Net Income. The effective tax rate was high at approximately 41.5%; against a 33.2% increase in Profit Before Tax (¥3.82B, +3.3% year on year), Net Income growth was limited to 3.8%. Although both revenue and profit increased, the profit growth rate remained below the revenue growth rate, indicating room for improvement in terms of margins.

Key Financial Indicators

【Profitability】The Operating Income margin of 19.8% and Net Income margin of 12.1% were both high; however, the Operating Income margin declined by approximately 1.1pt from 20.9% in the same period of the previous year, indicating margin pressure from higher SG&A expenses.【Cash Flow Quality】The contributions from extraordinary income and non-operating income were small, and the majority of Net Income was based on recurring operating income. However, the effective tax rate was high at approximately 41.5%, and the growth in Profit Before Tax was not sufficiently converted into after-tax earnings.【Investment Efficiency】Annualized ROE was 6.5%, decomposed into a Net Income margin of 12.1% × total asset turnover of 0.474x × financial leverage of 1.14x. Low asset turnover and a conservative financial structure constrained ROE.【Financial Soundness】The Equity Ratio was 87.8% (86.1% in the previous year), while cash and deposits of ¥20.15B accounted for 38.8% of total assets. The Company maintained an extremely conservative financial base, with a current ratio exceeding 600%.

Cash Flow Analysis

Although the cash flow statement has not been disclosed directly, funding trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥20.15B, a decrease of ¥1.41B from ¥21.56B in the same period of the previous year. Meanwhile, accounts receivable increased by 15.3% to ¥5.75B, while accounts payable decreased by 30.4% to ¥2.41B. The growth in operating receivables and reduction in trade payables may have increased the amount of funds tied up in working capital, contributing to the decline in cash balances. Investment securities increased from ¥0.78B to ¥1.11B, suggesting that a portion of surplus funds was invested in securities, which also appears to have contributed to the decline in cash. Cash represented 38.8% of total assets, remaining high and indicating ample liquidity.

Quality of Earnings

The majority of Current Period Profit was based on recurring operating income, and earnings quality was generally sound. Extraordinary income consisted solely of a ¥0.03B gain on the sale of fixed assets, representing only 1.3% of Net Income, while extraordinary losses were limited to a ¥0.001B loss on the disposal of fixed assets. Accordingly, temporary factors did not significantly affect performance. Non-operating income was ¥0.15B, or 0.8% of revenue, and consisted primarily of ¥0.02B in dividend income and ¥0.01B in foreign exchange gains, indicating a low degree of reliance on non-core income. Nevertheless, the high effective tax rate of 41.5% constrained the conversion of Profit Before Tax into Net Income, and the fact that Net Income growth was limited to +3.8% compared with Profit Before Tax growth of +3.3% should be noted when evaluating earnings growth. In addition, the upward trend in accounts receivable and inventories warrants monitoring of the cash conversion of earnings from an accruals perspective.

Earnings Forecast and Guidance

Progress against the full-year Company forecast was 76.9% for Revenue, 81.3% for Operating Income, 82.7% for Ordinary Income, and 76.5% for Net Income, all exceeding the standard progress rate of 75%. Progress for Operating Income and Ordinary Income was particularly high; however, the full-year Company forecast assumes Operating Income growth of only +0.3%, indicating a plan that incorporates a lower profit margin in Q4 than in the cumulative period. The levels required in Q4 are Revenue of ¥5.53B and Operating Income of ¥0.84B, representing a margin of 15.2%. As this is below the cumulative actual margin of 19.8%, the hurdle for achieving the plan is not high.

Shareholder Returns

The dividend for Q2 was ¥50.00 per share, and the full-year dividend forecast is ¥100.00 per share. Based on full-year forecast EPS of ¥200.75, the Payout Ratio is approximately 49.8%, below the 60% level generally viewed as an indicator of sustainability. As the amount of share repurchases cannot be confirmed from the disclosed data, the Total Return Ratio has not been calculated. Retained earnings of ¥38.19B and cash and deposits of ¥20.15B indicate substantial financial capacity to fund dividends.

Risk Factors

1. Deterioration in working capital efficiency: Accounts receivable of ¥5.75B increased by +15.3% year on year, while inventories also remained at a high level. Annualized CCC was 151 days, and the length of time funds remain tied up relative to the expansion of revenue and earnings warrants monitoring.

2. Margin pressure from higher SG&A expenses: SG&A expenses increased by +13.8% year on year, outpacing revenue growth of 6.5%. If this trend continues, maintaining the current Operating Income margin of 19.8% may become difficult.

3. High tax burden: The effective tax rate was high at approximately 41.5%, creating a structure in which Profit Before Tax growth is not sufficiently converted into Net Income or ROE. As the Company operates a single segment—the manufacture and sale of medical devices—it should also be noted that it is difficult to diversify and absorb the impact of demand fluctuations and regulatory developments.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Profitability is significantly above the industry median, placing the Company among the industry leaders in terms of profitability.

Growth and Capital Efficiency

The revenue growth rate also exceeds the industry median, and the trend of revenue growth is relatively solid within the industry.

※Source: Company analysis

Key Points from the Financial Results

1. The Operating Income margin of 19.8% and Net Income margin of 12.1% are significantly above the industry median; however, the Operating Income margin declined by approximately 1.1pt year on year due to higher SG&A expenses, indicating a change in the conversion rate of revenue growth into profit.

2. The robust financial base, comprising cash and deposits of ¥20.15B, a current ratio exceeding 600%, and an Equity Ratio of 87.8%, demonstrates resilience to business fluctuations. On the other hand, annualized ROE of 6.5% is relatively low from a capital-efficiency perspective.

3. Although the progress rate for Operating Income against the full-year forecast was 81.3%, exceeding the standard progress rate, the lengthening of the working capital cycle due to increases in accounts receivable and inventories—annualized CCC of 151 days—warrants attention from the perspective of future funding efficiency.

Theoretical Share Price (Reference Value)

Sensitivity: ¥2,748–¥2,901 at ±1% for the cost of equity, and ¥2,813–¥2,829 at ±0.1 for ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used; there is a timing difference from the full-year forecast.
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---